178 related articles for article (PubMed ID: 10848782)
1. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma.
Matsuo Y; Drexler HG; Nishizaki C; Harashima A; Fukuda S; Kozuka T; Sezaki T; Orita K
Br J Haematol; 2000 Apr; 109(1):54-63. PubMed ID: 10848782
[TBL] [Abstract][Full Text] [Related]
2. Induction of CD28 on the new myeloma cell line MOLP-8 with t(11;14)(q13;q32) expressing delta/lambda type immunoglobulin.
Matsuo Y; Drexler HG; Harashima A; Okochi A; Hasegawa A; Kojima K; Orita K
Leuk Res; 2004 Aug; 28(8):869-77. PubMed ID: 15203285
[TBL] [Abstract][Full Text] [Related]
3. Human bone marrow stroma-dependent myeloma sister cell lines MOLP-6 and MOLP-7 derived from a patient with multiple myeloma.
Harashima A; Matsuo Y; Nishizaki C; Kozuka T; Fukuda S; Sezaki T; Orita K
Hum Cell; 2000 Mar; 13(1):43-54. PubMed ID: 10937346
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of new IgD lambda type myeloma cell lines, MOLP-2 and MOLP-3, expressing CD28, CD33 antigens and the IL-6 receptor.
Matsuo Y; Nakamura S; Adachi T; Tsubota T
Hum Cell; 1993 Dec; 6(4):310-3. PubMed ID: 8148313
[TBL] [Abstract][Full Text] [Related]
6. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
Blood; 1997 Sep; 90(5):1960-7. PubMed ID: 9292530
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
[TBL] [Abstract][Full Text] [Related]
8. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals.
Lombardi VR; García M; Rey L; Cacabelos R
J Neuroimmunol; 1999 Jun; 97(1-2):163-71. PubMed ID: 10408971
[TBL] [Abstract][Full Text] [Related]
9. The clonal hierachy in multiple myeloma.
Rasmussen T; Jensen L; Johnsen HE
Acta Oncol; 2000; 39(7):765-70. PubMed ID: 11145430
[TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2).
Van Riet I; De Greef C; Aharchi F; Woischwill C; De Waele M; Bakkus M; Lacor P; Schots R; Van Camp B
Leukemia; 1997 Feb; 11(2):284-93. PubMed ID: 9009094
[TBL] [Abstract][Full Text] [Related]
11. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.
Jourdan M; Ferlin M; Legouffe E; Horvathova M; Liautard J; Rossi JF; Wijdenes J; Brochier J; Klein B
Br J Haematol; 1998 Mar; 100(4):637-46. PubMed ID: 9531328
[TBL] [Abstract][Full Text] [Related]
12. A novel mature B-cell line (DOBIL-6) producing both parathyroid hormone-related protein and interleukin-6 from a myeloma patient presenting with hypercalcaemia.
Ohmori M; Nagai M; Fujita M; Dobashi H; Tasaka T; Yamaoka G; Kawanishi K; Taniwaki M; Takahara J
Br J Haematol; 1998 Jun; 101(4):688-93. PubMed ID: 9674742
[TBL] [Abstract][Full Text] [Related]
13. The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(11;14)(q13;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia.
Kubonishi I; Seto M; Shimamura T; Enzan H; Miyoshi I
Cancer; 1992 Sep; 70(6):1528-35. PubMed ID: 1516003
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific aneuploidy not detected in CD19+ B-lymphoid cells from myeloma patients in a multidimensional flow cytometric analysis.
McSweeney PA; Wells DA; Shults KE; Nash RA; Bensinger WI; Buckner CD; Loken MR
Blood; 1996 Jul; 88(2):622-32. PubMed ID: 8695810
[TBL] [Abstract][Full Text] [Related]
15. Establishment and biological characteristics of human multiple myeloma cell line CZ-1.
Hou J; Lin FY; Zhang B; Zhang LZ; Ding SQ
Chin Med J (Engl); 2004 Jan; 117(1):115-9. PubMed ID: 14733786
[TBL] [Abstract][Full Text] [Related]
16. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain.
Bergsagel PL; Smith AM; Szczepek A; Mant MJ; Belch AR; Pilarski LM
Blood; 1995 Jan; 85(2):436-47. PubMed ID: 7529064
[TBL] [Abstract][Full Text] [Related]
17. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells.
Leo R; Boeker M; Peest D; Hein R; Bartl R; Gessner JE; Selbach J; Wacker G; Deicher H
Ann Hematol; 1992 Mar; 64(3):132-9. PubMed ID: 1373957
[TBL] [Abstract][Full Text] [Related]
18. [Detection of myeloma cells in the peripheral blood using flow cytometry].
Adam Z; Klabusay M; Vorlícek J; Hájek R
Vnitr Lek; 1997 Sep; 43(9):592-8. PubMed ID: 9750468
[TBL] [Abstract][Full Text] [Related]
19. The relationship of HLA-DR, CD38 and CD71 markers to activation, proliferation and differentiation of some human leukemia and lymphoma cells.
Glasová M; Koníková E; Stasáková J; Babusíková O
Neoplasma; 1998; 45(2):88-95. PubMed ID: 9687889
[TBL] [Abstract][Full Text] [Related]
20. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
